Protagenic Therapeutics, Inc.new (PTIX) stock
PTIXOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026
$0.75+0.00 (0.00%)
Close on Oct 19, 2026Market cap $1.36MP/E –Yield –
Protagenic Therapeutics, Inc.new operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Protagenic Therapeutics, Inc.new's operating cash flow for the twelve months ending Dec 31, 2024 was -$4.22M. For fiscal 2024 it was -$4.22M. The highest annual figure on record is -$487.99K in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$4.22M | – |
| FY2023 | Dec 31, 2023 | -$3.70M | – |
| FY2022 | Dec 31, 2022 | -$1.99M | – |
| FY2021 | Dec 31, 2021 | -$2.80M | – |
| FY2020 | Dec 31, 2020 | -$1.35M | – |
| FY2019 | Dec 31, 2019 | -$487.99K | – |
| FY2018 | Dec 31, 2018 | -$1.07M | – |
| FY2017 | Dec 31, 2017 | -$1.38M | – |
| FY2016 | Dec 31, 2016 | -$1.14M | – |
| FY2014 | Jun 30, 2014 | -$790.00K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ1 2026 | Jun 30, 2026 | -$944.30K | – |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | -$819.79K | – |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | -$185.66K | – |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | -$246.43K | – |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | -$1.66M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$1.14M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$655.77K | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$1.53M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$371.83K | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$180.94K | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$535.23K | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$847.08K | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$430.57K | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$405.09K | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$1.08M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$710.38K | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$607.71K | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$320.87K | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$517.81K | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$145.69K | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$364.41K | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$149.42K | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$61.76K | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$80.79K | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$196.02K | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$307.79K | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$159.63K | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$344.76K | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$259.01K | – |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | -$417.02K | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | -$358.80K | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | -$246.88K | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | -$357.40K | – |
| Q4 FY2016CQ4 2016 | Dec 31, 2016 | -$341.81K | – |
| Q3 FY2016CQ3 2016 | Sep 30, 2016 | -$296.07K | – |
| Q2 FY2016CQ2 2016 | Jun 30, 2016 | -$445.05K | – |
| Q1 FY2016CQ1 2016 | Mar 31, 2016 | -$57.39K | – |
See a number that looks wrong?